Ibis Therapeutics, an artificial intelligence platform company co-founded by Mayo Clinic, announced today its collaboration agreement with Mayo Clinic to accelerate the discovery of novel and repurposed drug candidates suitable for clinical development.
Under the agreement, Mayo Clinic will invest to help Ibis expand the scope of its platform in identifying best-in-class compounds with fewer side effects. Mayo Clinic researchers will lead and participate in preclinical and clinical studies to validate this approach of accelerating the identification of novel, safe, and efficacious compounds. The initial focus on addressing critical issues in inflammation and immunology affecting significant patient populations has the potential to be expanded into additional therapeutic areas..
Ibis’ Molecular Fingerprint™ platform examines all possible interactions between diverse arrays of drug candidates with the largest curated collection of both disease-modifying and toxicity-causing protein targets. The reproducible generation of unbiased efficacy and safety fingerprints at scale greatly reduces lengthy design-make-test cycles, thereby allowing rapid convergence to clinical candidates.
“We are excited to combine Mayo Clinic’s vast clinical and translational expertise with our ability to quickly identify compounds with desirable properties to address unmet medical needs. Mayo Clinic has been a strong advocate for the use of innovative AI-driven technology platforms to advance healthcare, and we look forward to our collaboration to change patient outcomes” said Sam Shrivastava, Founder, CEO and Chairman of Ibis Therapeutics. “Molecular Fingerprint™ can be used as a horizontal platform by clinician-researchers across Mayo Clinic’s many vertical areas of therapeutic expertise. This agreement will further advance our work and provide a path towards reaching patients.”
About Ibis
Ibis is defining the future of precision medicine by revealing a unique AI-driven Molecular Fingerprint™ of how a drug interacts with all relevant targets in a cell. The Molecular Fingerprint™ engine can drive discovery of both novel and repurposed drug candidates for critical unmet needs with superior efficacy and a clear safety profile. Molecular Fingerprint™ disrupts the current paradigm of “one disease-one target-one drug” allowing polypharmacology, selectivity profiling, safety assessments, and drug repurposing to be integrated into all stages of drug discovery and development. This can lead to the development of better drugs and faster times towards clinic and eventual FDA approval.
To learn more about Ibis and its mission to reimagine how drugs are discovered and developed, please visit www.ibistx.com.